Invention Grant
- Patent Title: Imidazole and triazole containing bicyclic compounds as JAK inhibitors
-
Application No.: US16949280Application Date: 2020-10-23
-
Publication No.: US11339160B2Publication Date: 2022-05-24
- Inventor: Robert Murray McKinnell , Erik Fenster , Tom M. Lam , Anthony Francesco Palermo
- Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
- Applicant Address: US CA South San Francisco
- Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
- Current Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
- Current Assignee Address: US CA South San Francisco
- Agency: Sheppard Mullin Richter & Hampton LLP
- Agent Jeffrey A. Hagenah
- Main IPC: C07D471/04
- IPC: C07D471/04 ; A61P1/00 ; A61K9/00 ; C07D471/08 ; C07D487/04 ; C07D487/08
Abstract:
The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat gastrointestinal and other inflammatory diseases.
Public/Granted literature
- US20210040085A1 IMIDAZOLE AND TRIAZOLE CONTAINING BICYCLIC COMPOUNDS AS JAK INHIBITORS Public/Granted day:2021-02-11
Information query
